Equity Overview
Price & Market Data
Price: $2.11
Daily Change: -$0.09 / 4.27%
Range: $2.05 - $2.20
Market Cap: $149,720,528
Volume: 453,122
Performance Metrics
1 Week: 16.57%
1 Month: 54.01%
3 Months: -15.26%
6 Months: -49.28%
1 Year: -72.09%
YTD: -15.26%
Company Details
Employees: 157
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.